Investors Asset Management of Georgia Inc. GA ADV Buys 630 Shares of Eli Lilly and Company (NYSE:LLY)

Investors Asset Management of Georgia Inc. GA ADV lifted its stake in Eli Lilly and Company (NYSE:LLY) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,894 shares of the company’s stock after buying an additional 630 shares during the quarter. Eli Lilly and Company makes up 2.6% of Investors Asset Management of Georgia Inc. GA ADV’s holdings, making the stock its 5th largest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Eli Lilly and Company were worth $5,165,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JGP Wealth Management LLC raised its stake in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares in the last quarter. Cassia Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after purchasing an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC increased its position in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares during the period. Patton Albertson Miller Group LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after acquiring an additional 17 shares during the period. Finally, Valley Wealth Managers Inc. increased its holdings in shares of Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on LLY. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Barclays increased their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 0.7 %

LLY traded down $5.04 during trading on Thursday, hitting $745.73. The company’s stock had a trading volume of 844,605 shares, compared to its average volume of 3,055,587. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The firm’s 50 day moving average price is $764.03 and its 200-day moving average price is $657.67. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market cap of $708.56 billion, a PE ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.09 earnings per share. On average, analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.